Natural remedies. by unknown
Many ofthe environmental hazards begin in a far more serious concentration as occupational hazards on the job.
Ralph Nader,testimony,




When Walter Lewis and his team of
researchers first visited the Jivaro Indians of
Peru in the 1980s, they wanted to know
why the tribespeople chewed the leaves ofa
local plant to blacken their teeth; was it
merely aesthetic or was there a therapeutic
reason behind the practice? While it was
immediately clear that the leaf extracts
helped seal the teeth, the Washington
University researcher later discovered
through chemical analysis that the extracts
contained traces offluoride.
This potential in combining native wis-
dom with western research recently
prompted three U.S. government agencies
to initiate and support an unprecedented
program to search the rainforests and
deserts of South and Central America as
well as Africa for natural medicinal thera-
pies. Rainforests (due to their mild climate)
are especially rich in plant and insect
species, which have developed a high num-
ber of chemical compounds to help them
ward off an abundance of natural enemies.
The harsh conditions ofdeserts force plants
to develop unique chemicals that may be
useful in human pharmaceutical research.
Chosen from 34 submissions in late
1993, 5 independent research teams will
spend 5 years examining plants and insects
for possibilities of a treatment or cure for
such illnesses as AIDS, cancer, parasitic dis-
eases, arthritis, and heart disease. The teams
will share $2.5 million per year through the
program jointly sponsored by the National
Institutes of Health, the U.S. Agency for
International Development, and the
National Science Foundation.
The research teams, called International
Cooperative Biodiversity Groups (ICBGs),
each include specialists from American uni-
versities, botanical gardens, and drug com-
panies as well as scientific and cultural
experts within the various host countries.
Along with chemical prospecting, the teams
plan to help local communities cultivate
medicinal plants into cash crops while pre-
serving their region's biodiversity. This
multidisciplinary and multiethnic approach
supports the program's central philosophy
that the benefits and proceeds of any suc-
cessful research must be shared with every-
one involved, including traditional healers.
"There were several principles that we
decided were critical to this kind ofresearch
Plant lore. Ethnobotanist Mark J. Plotkin is working with Tirio Indian colleagues in Suriname to discover
new medicines from tropical plants.
program," says Francesca Grifo, ICBG pro-
gram manager at the NIH Fogarty
International Center. "The research must
do no harm to the tribal communities, it
must be sustainable, and traditional healers
must be closely involved."
Mark Plotkin, an ethnobotanist (a sci-
entist who studies the plant lore ofa race or
people) with the Washington-based
Conservation International, author of the
book Tales ofa Shaman'sApprentice and an
ICBG member, says that in the past "these
[native] people were often ripped off. Now
we hope to basically reinvent ethnobotany,
to do things right by putting together a
win-win program that involves full consent
and full exposure."
The research program also reflects a
trend in American pharmaceutical research
toward tapping the ancient wisdom oftribal
medicine. While botanists, entomologists,
and tribal members will conduct most of
the field research, drug manufacturers will
later screen the teams' plants and insects for
therapeutic activity and conduct the costly
clinical trials required by the FDA to allow
a newdrug onto the market.
Since 1989, Monsanto Company and
its pharmaceutical subsidiary Searle have
been conducting bioassays on the extracts
from medicinal plants Lewis brought back
from the Peruvian Andes. Now a member
of Lewis's ICBG, Monsanto's involvement
is a sign ofthe industry's "resurgent interest
in plants," according to Monsanto's
Associate Program Leader David Corley.
"And we've had some very exciting hits
with Dr. Lewis, including a possible extract
for arthritis."
For decades, drug studies relied on the
random and often slow testing ofchemical
molecules and recently of enzyme activity
in genetic material. As a result of that
research, highly sensitive technology and
methods are now readily available, and
hundreds of medicinal compounds can be
screened in a week, according to David
Kingston, chemist at Virginia Polytechnic
Institute and State University and an
ICBG collaborator.
"Pharmaceutical companies now need a
large number ofcompounds to run through
their screens," says Kingston, whose team
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will study the rainforests ofSuriname. "And
gums, tars, resins, insects, and leaves pro-
vide a wonderful source ofnew compounds
that can be tested very efficiently and quick-
ly. Even the tiniest compounds can now be
picked up."
A number of plant-based drugs are
already available, including the antitumor
compound Taxol, made from the bark of
the yew tree. But using plants as an impor-
tant medicinal source can bring its own set
of problems. In the Pacific Northwest of
the United States, primary forests ofmature
yew trees were decimated because of heavy
harvesting to make Taxol. Today, the com-
pound is made semisynthetically, using only
the tree's needles, according to Kingston.
By helping local communities cultivate
medicinal plants, the ICBG members hope
to avoid the Taxol example.
While four of the teams will focus on
plants, a team of entomologists from
Cornell University plans to study some of
the tens ofthousands ofinsects found in the
dry tropical forests ofCosta Rica, according
to Cornell entomologist and ICBG member
Thomas Eisner. Insects have long been
overlooked for their medicinal potential
despite several recent discoveries such as
active antiviral compounds found in fire-
flies. "Because insects are often tiny and eas-
ily threatened in their environments, they
have had to create chemical defenses," says
Eisner. "We think this could be a new kind
of treasure." However, such rainforests are
shrinking as a result of regional develop-
ment, so there is an urgency to accelerate
research and collaboration.
"Most natural compounds have not yet
been discovered," says Eisner. "And many
species are fast disappearing, which is a
great shame because the best things on the
market are all derived from nature."
Ethnobotanists believe desert plants
may also produce promising medicinal
compounds. Unable to move or escape,
desert organisms have had to adapt,
anatomically and chemically, to high heat,
intense sun, and lack of water. In order to
survive, theyproduce "many unusual chem-
icals to protect themselves," says ICBG
member Barbara Timmermann, a phyto-
chemist at the University ofArizona. These
chemicals can then be studied for their ther-
apeutic activity in human disease.
Timmermann's team will be working
closely with native healers to carefully select
plants from the hundreds of species that
inhabit the hot deserts ofChile and the cold
deserts of southern Argentina, especially
Patagonia and Tierra del Fuego. Because of
the preliminary nature of their work,
Timmerman is reluctant to identify any
particular plant that might have potential.
Like her colleagues on other ICBGs, she
fears that until toxicological studies prove a
plant harmless, sick people
may gather its leaves and try
to treat themselves.
Silicon Lungs
Open to the environment,
the lung's airways continu-
ously take in the atmos-
phere and process the good
and the bad through a
branching maze of bronchi
and alveolar air sacs. Just
how-and how much-
pollution affects human
lungs has largely remained a
mystery. One institution,
the Center for Extrapo-
lation Modeling at Duke
University Medical Center, is making
progress in understanding how human
lungs interact with environmental toxins.
Researchers at the center, formed in 1986
with the help ofEPA and industry funding,
are now able to demonstrate, for example,
what a summertime's exposure to ozone
and freeway gases in LosAngeles does to the
lungs of a rat. The center's 10-member
team ofrespiratory physiologists, cell biolo-
gists, engineers, and mathematicians is now
calculating how equivalent doses of pollu-
tants affect human lungs.
Using data on lung structure and orga-
nization from a variety ofdifferent types of
pathologic analyses, the center is slowly and
steadily deriving a computer-based, three-
dimensional model of both animal and
human lungs that can be used to help pre-
dict where different doses of a particular
pollutant will cause damage. The task is
extremely complicated given that only lim-
ited data are available from human studies,
said the center's director, James D. Crapo.
"We have to create a database to predict
effects which are unknown or for which
data cannot be accumulated," he said.
Currently, the EPA sets air quality stan-
dards based on human epidemiologic stud-
ies and on animal studies using the assump-
tion that ifa certain pollutant causes injury
in animals, then it must also be harmful to
humans. What isn't known, said Crapo, is
what concentrations of common air pollu-
tants cause injury in humans and exactly
where that damage occurs. "Our goal is to
find ways to predict where in the lungs dif-
ferent pollutants go, their dose at specific
sites, and the types ofdamages they cause,"
he said.
The center's researchers are using the
only data available to them-known effects
of air pollution in studies of animal lungs.
Then, using mathematical modeling, the
researchers derive experimental correlations
that can provide input for extrapolation





Virtual reality. Computer-based models of rat lungs may help show
where pollutants lodge in lungs of humans.
mals to humans, said Crapo.
It's an intricate process. Animal lungs
behave differently from human lungs. The
lungs of a rat have airways that are shaped
like a pine tree because of their straight,
monopodial branching system. But human
lungs, with airways that have an irregular,
dichotomous branching pattern, are more
like an oak tree. Because of this, particles
and gas that might be absorbed in one area
in rat lungs would likely be processed in a
different place in human lungs. Each
species also has varying types ofcells in dif-
ferent locations in their lungs.
To determine these differences and eval-
uate their significance, scientists at the cen-
ter are conducting toxicology studies ofcells
of the alveolar regions and small airways of
animals exposed to varying doses of differ-
ent airborne pollutants. These data are
gathered by techniques such as immunocy-
tochemistry, in situ hybridization, electron
microscopy, and magnetic resonance
microscopy. Researchers at the center are
also leading the field in gathering micro-
dosimetry data, the calculation ofpollution
dose at specific cells in each ofthe different
regions ofthe lungs using labeled gases and
particles in combination with microscopy,
autoradiography, or positron emission
tomography. "In five years we'd like to have
developed a computer system that simulates
every aspect of the process of breathing
based on all the data we've collected," said
Crapo. "We could introduce different pol-
lutants into the system and determine in
real-time exactly where in the lungs they
go.
Philip Bromberg, director of the
University of North Carolina Center for
Environmental Medicine and Lung Biol-
ogy, says the Duke lung modeling program
is as ambitious as it is unique. "With a
structure as complicated as a lung, it is diffi-
cult to reconstruct a 3-D piece of even a
small portion. This is not like a piece of
bologna, where you can figure out what the
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